Jack L. Wyszomierski Sells 8,287 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXELGet Free Report) Director Jack L. Wyszomierski sold 8,287 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the sale, the director now owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Exelixis Stock Down 1.4 %

NASDAQ:EXEL opened at $21.88 on Friday. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $24.34. The stock has a fifty day simple moving average of $22.22 and a 200-day simple moving average of $22.30. The company has a market capitalization of $6.63 billion, a PE ratio of 34.19, a price-to-earnings-growth ratio of 0.54 and a beta of 0.56.

Exelixis (NASDAQ:EXELGet Free Report) last announced its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). The business had revenue of $425.23 million for the quarter, compared to analyst estimates of $461.04 million. Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.12 EPS. As a group, equities analysts anticipate that Exelixis, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on EXEL shares. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. Stephens assumed coverage on Exelixis in a research note on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. TD Cowen lifted their price objective on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Barclays downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research report on Thursday, April 11th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.13.

Get Our Latest Research Report on EXEL

Institutional Investors Weigh In On Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. raised its holdings in shares of Exelixis by 31.5% in the third quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company’s stock worth $30,811,000 after acquiring an additional 338,021 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Exelixis by 236.3% in the 4th quarter. State of Alaska Department of Revenue now owns 127,287 shares of the biotechnology company’s stock valued at $3,053,000 after purchasing an additional 89,436 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Exelixis by 244.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company’s stock valued at $2,839,000 after purchasing an additional 83,999 shares in the last quarter. Advisors Preferred LLC acquired a new stake in shares of Exelixis during the 4th quarter worth about $3,384,000. Finally, Seven Eight Capital LP boosted its position in Exelixis by 61.7% during the third quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 8,305 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

About Exelixis

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Read More

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.